A study to evaluate the impact of nephrotic syndrome on the steady state pharmacokinetics and pharmacodynamics of edoxaban compared to health volunteers, and whether edoxaban can provide an equivalent anticoagulant effect to enoxaparin sodium.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
area under the steady-state plasma concentration-time curve (AUCss)
Timeframe: Day 4 post-administation
time to peak (Tmax)
Timeframe: Day 4 post-administation
trough concentration at steady state (Css_min)
Timeframe: Day 4 post-administation
peak concentration at steady state (Css_max)
Timeframe: Day 4 post-administation
elimination half-life (t1/2)
Timeframe: Day 4 post-administation
average steady-state plasma concentration (Css_av)
Timeframe: Day 4 post-administation]
apparent volume of distribution (Vd/F)
Timeframe: Day 4 post-administation
clearance (CL/F)
Timeframe: Day 4 post-administation
anti-FXa activity
Timeframe: Day 4 post-administation
prothrombin time (PT)
Timeframe: Day 4 post-administation
activated partial thromboplastin time(APTT)
Timeframe: Day 4 post-administation
antithrombin â…¢(AT-III)
Timeframe: Day 4 post-administation
Protein C
Timeframe: Day 4 post-administation
Protein S
Timeframe: Day 4 post-administation
D-Dimer
Timeframe: Day 4 post-administation